Title:
Ambisome plus miltefosine for Indian patients with kala-azar

Simple item page
dc.contributor.authorShyam Sundar
dc.contributor.authorPrabhat Kumar Sinha
dc.contributor.authorDeepak K. Verma
dc.contributor.authorNawin Kumar
dc.contributor.authorShahnawaj Alam
dc.contributor.authorKrishna Pandey
dc.contributor.authorPoonam Kumari
dc.contributor.authorVidyanand Ravidas
dc.contributor.authorJaya Chakravarty
dc.contributor.authorNeena Verma
dc.contributor.authorJonathan Berman
dc.contributor.authorHashim Ghalib
dc.contributor.authorByron Arana
dc.date.accessioned2026-02-07T05:28:22Z
dc.date.issued2011
dc.description.abstractThe combination of one intravenous administration of 5. mg/kg Ambisome and oral administration of miltefosine, 2.5. mg/kg/day for 14 days, was evaluated in 135 Indian patients with kala-azar. The Intent-to-Treat cure rate at 6 months was 124 of the 135 enrolled patients (91.9%: 95% CI = 86-96%), and the per protocol cure rate was 124 of 127 evaluable patients (97.6%: 95% CI = 93-100%). Side effects could be attributed to each drug separately: fevers, rigors and back pain due to Ambisome; gastrointestinal side effects due to miltefosine. This combination is attractive for reasons of efficacy, tolerance, and feasibility of administration, although the gastrointestinal side effects of miltefosine require medical vigilance. Clinical Trials.gov identification number: NCT00371995. © 2010 Royal Society of Tropical Medicine and Hygiene.
dc.identifier.doi10.1016/j.trstmh.2010.10.008
dc.identifier.issn359203
dc.identifier.urihttps://doi.org/10.1016/j.trstmh.2010.10.008
dc.identifier.urihttps://dl.bhu.ac.in/bhuir/handle/123456789/23124
dc.subjectAmbisome
dc.subjectCombination therapy
dc.subjectEfficacy
dc.subjectKala-azar
dc.subjectMiltefosine
dc.subjectVisceral leishmaniasis
dc.titleAmbisome plus miltefosine for Indian patients with kala-azar
dc.typePublication
dspace.entity.typeArticle

Files

Collections

2011
An Initiative by BHU – Central Library
Powered by Dspace